UK-listed drugs company GlaxoSmithKline’s (GSK) new strategic corporate venturing fund for bioelectronic medicines and technologies has joined a consortium to investing in the $27m series D round for SetPoint Medical, a US-based biomedical technology company. Alongside GSK’s Action Potential Venture Capital fund in the round were corporate venturing peers from healthcare companies Covidien and Boston…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
